


Economic evaluation in healthcare programmes and interventions

Yot Teerawattananon M.D., Ph.D.



Concerns in health technology/policy adoption

- Safety
- Efficacy/Effectiveness (benefits)
- Value for money (economic evaluation)
- Social, institutional and ethical implications
- Affordability






Economic Evaluation

"... the comparative analysis of alternative courses of action in terms of both their costs and consequences."

Drummond, Stoddart & Torrance, 1987



3



Type of economic evaluation

	Nominator	Denominator	
Cost-minimization	\$	-	
Cost-effectiveness	\$	Process or health outcome in natural unit e.g. case detected (screening) or case averted (prevention & treatment)	
Cost-utility	\$	Outcome in a common unit e.g. QALY, DALY	
Cost-benefit	\$	\$	




Waste costs lives




Interventions that are in — and out


thanks to Chris McCabe and Richard Edlin for some animation of Culyer et al. (2007)



Interventions that are in — and out




Interventions that are in — and out






Policy cycle model



Buse K, Mays N, Walt G. Making health policy (understanding public health). UK: Bell & Brain Ltd. 2005.



Policy cycle model



2005.



A case study in Myanmar



Health Policy and Planning Advance Access published September 26, 2015

Health Policy and Planning, 2015, 1–11 doi: 10.1093/heapol/czv090 Original Manuscript



Original Manuscript

An ex-ante economic evaluation of the Maternal and Child Health Voucher Scheme as a decision-making tool in Myanmar


Pritaporn Kingkaew,^{1,*} Pitsaphun Werayingyong,¹ San San Aye,² Nilar Tin,³ Alaka Singh,⁴ Phone Myint² and Yot Teerawattananon¹

Pilasant et al. BMC Health Services Research (2016) 16:600 DOI 10.1186/s12913-016-1850-3

BMC Health Services Research

RESEARCH ARTICLE

Open Access





Songyot Pilasant¹, Wantanee Kulpeng¹, Pitsaphun Werayingyong^{1*}, Nattha Tritasavit¹, Inthira Yamabhai¹, Yot Teerawattananon¹, Sangay Wangmo² and Sripen Tantivess¹



Summary of the policy process and HTA for MCHVS in Myanmar

Stages heuristic	Agenda setting	Formulation	Implementation	Evaluation
Type of studies	Situation analysis	Ex-ante HTA	On-going HTA	Ex-post HTA
Year	2008	2010-11	2013	2016-17
Objectives	Setting policy direction, goal(s) and target(s)	 Predict likely costs and impact Assess value for money and financial and program feasibility to inform decision makers to select the best possible option 	- Evaluate key parameters to direct more effective program implementation and ensure impact.	- Assess whether the program achieved its goal
Approach	Stakeholder consultation, health system gap analysis	Document review Consultations Evidence synthesis Model-based evaluation	Self-reported questionnaires Collection and analysis of hospital utilization data Focus group discussions and interviews Direct observation	Document review Self-assessment form Analysis of M&E data Household survey
Key results	The need to address issues of high out-of-pocket health expenditures and inability to pay for maternal and child health services provided by skill-birth attendants	Key interventions and their likely cost and value for money determined	Willingness of target populations to participate in the MCHVS, adherence to intervention protocol by providers and end-users	Targeting of beneficiaries is key. Effective in reducing out of pocket expenditure.
Implication for the next phase	Impetus for community health insurance scheme	Key parameters for implementation success developed.	Recommendations to improve implementation	Knowing whether MCHVS should be continued using other financial sources



Methodological Approach for Measuring the Impact of HTA

Potential Impact

HTA: Economic modelling – population health impact – full implementation

Theory based approach

Eleanor Grieve & Andrew Briggs 2015



Table 2: Potential net health benefits

	Ex-ante GBP £	Ex-post GBP £
Incremental cost	96	94
Incremental life year saved	0.2513	0.2782
Incremental DALY averted	0.2531	0.2789
ICER per DALY averted	384	336

GDP Myanmar (2010)

414

Threshold used = 1 GDP

NHBs = $\Delta H - \Delta C/\lambda$

Net health benefits (per person) 0.02 0.05

Scaled to pilot (11532 pregnant women) 231 DALYS 576 DALYS




Teerawattananon et al. Globalization and Health 2013, **9**:35 http://www.globalizationandhealth.com/content/9/1/35



REVIEW Open Access

Health technology assessments as a mechanism for increased value for money: recommendations to the Global Fund

Yot Teerawattananon^{1*}, Kate McQueston², Amanda Glassman², Jomkwan Yothasamut^{1,2} and Chaw Yin Myint^{1,2}





http://ijhpm.com Int J Health Policy Manag 2017, 6(x), 1–5

doi 10.15171/ijhpm.2017.25





Debate

How Should Global Fund Use Value-for-Money Information to Sustain its Investments in Graduating Countries?



Kitti Kanpirom¹, Alia Cynthia G. Luz^{2*}, Kalipso Chalkidou³, Yot Teerawattananon⁴




Figure. VFM of Possible Global Fund Programs/Interventions. Abbreviation: VFM, value-for-money.



Points for discussion

- Methodological difficulties in conducting health economic evaluations at various stages of policy process
- Potential of using health economic evaluation to inform global health donors
- Measuring HTA impact